Crown Bioscience to Showcase Novel “in life” Platforms for Oncology Drug Discovery at the AACR Annual Meeting 2014

Crown Bioscience, Inc., a leading global drug discovery and development service company, will be highlighting its expertise in Oncology Drug Discovery on booth #2111 at the AACR (American Association of Cancer Research) Annual Meeting, on April 5th – 9th 2014, San Diego Convention Center, San Diego, California. Via a series of poster presentations Crown Bioscience will demonstrate its commitment to finding new ways to improve drug discovery and development, enabling clients to significantly accelerate their research programs and make better informed decisions about which compounds to progress into clinical trials.

At AACR, Crown Bioscience will unveil its novel “in life” platforms for Oncology. Building on the success of its recent agreement with Shanghai Institute of Materia Medica to develop the world’s leading mouse clinical trial (MCT) center in China, Crown Bioscience plans to continue to develop the largest and most advanced fully annotated collections of Patient-Derived Xenograft (PDX) models. PDX models “came-of-age” in 2013 with a massive growth in their application by the oncology research community.

Phase II-like trials

Crown Bioscience will also provide an insight into how a large collection of high quality, highly characterized models ready for screening, enables drug discovery companies to run Phase II-like trials using PDX as human surrogate models. Crown Bioscience’s large collection of PDX models (HuPrime©) and HuBase™ (a comprehensive database of genotypic, pharmacological and clinical data of HuPrime models) enable drug discovery organizations to identify genetic signatures of disease, discover and validate biomarkers and perform human surrogate Phase II-like trials (also known as “Avatar” trials) by selecting patient responders and non-responders and evaluating efficacy in models that come from the direct lineage of a patient’s tumor.

More patient-relevant disease models

Jean-Pierre Wery, President of Crown Bioscience comments, “Our mission is to provide the “gold-standard” collection of well-characterized models and services for drug discovery to help our clients reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic.” He continues, “Our mission is to deliver the results our customers need. As drug discovery continues to rapidly evolve, there is a growing desire to screen candidates earlier with more patient-relevant disease models - models which more closely reflect the patient situation in the clinic and therefore help improve the selection of candidates that are taken forward.”

Crown Bioscience has a global footprint, spanning three major continents in North America, Europe and Asia Pacific. The company offers a unique collection of ready-to-run, well-validated in vitro and in vivo models, model development expertise, comprehensive drug discovery platforms and global capacity to help clients quantify the real efficacy and pharmacological profile of their candidate before they move into the clinic. As the largest supplier of translational oncology services, Crown Bioscience is committed to providing its pharmaceutical and biopharmaceutical customers with specialized techniques and services to help the world-wide research community turn cancer from an incurable into a manageable, chronic disease and discover new targets and therapies in the treatment of metabolic diseases.

At AACR, the following posters will be presented:

• Patient relevant preclinical in vivo models using image-guided small animal irradiation for drug discovery
Session ID: Tumor Biology 24
Monday April 7, 2014, 1:00pm - 5:00pm, Hall A-E, Poster Section 7

•In vivo and in vitro generation and characterization of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations
Session ID: Tumor Biology 47
Wednesday April 9, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 3

• Modeling anti-leukemic therapy by patient derived AML xenografts with distinct phenotypes/geneotypes
Session ID: Tumor Biology 32
Tuesday April 8, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 7

• Parameters influencing the design of mouse clinical trial (HuTrial™)
Session ID: Tumor Biology 18
Monday April 7, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 9

• Evaluate in vivo efficacy of anti-tumor immuno-therapeutics using Mixeno™ mouse models
Session ID: Immunology 4
Monday April 7, 2014, 1:00pm - 5:00pm, Hall A-E, Poster Section 27

• Xenograft models for development of new drugs targeting fibroblast growth factor receptor (FGFR)
Session ID: Tumor Biology 32
Tuesday April 8, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 7

• X-MAN™ isogenic DualXeno™ models with KRAS mutation predicts the effect of anti-EGFR agents
Session ID: Tumor Biology 32
Tuesday April 8, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 7